Recently, triptolide downregulated CXCL12 in subcutaneous colon cancer tumors, which in turn reduced TAM infiltration, reduced tumorsupportive M2 polarization, and decreased the expression of CD206 and IL-10 (163). This evidence concerns the gene CXCL12 and malignant colon neoplasm.